In addition to its subcutaneous route of delivery instead of intravenous infusion, Fazizi said that no renal monitoring or dose adjustment is needed with denosumab as opposed to zoledronic acid, nor is there a need to manage acute-phase reactions. To date, more than 11,000 patients have been exposed to denosumab in clinical trials of patients with cancer or bone loss.
To sign up for our newsletter or print publications, please enter your contact information below.